The legal library gives you easy access to the FTC’s case information and other official legal, policy, and guidance documents.
20161004: Nippon Telegraph and Telephone Corporation; Denali Holding Inc.
20161020: Tsinghua Holdings Co., Ltd.; Marvell Technology Group Ltd.
20161030: KBHS Group Holdings, LLC; American Capital, Ltd.
20161039: Riverstone/Carlyle Global Energy and Power Fund IV (FT), L.P; Sanjel Corporation
20161040: Riverstone Global Energy and Power Fund VI, L.P.; Sanjel Corporation
1605002 Informal Interpretation
1605003 Informal Interpretation
Hikma Pharmaceuticals PLC, In the Matter of
Drug manufacturer Hikma Pharmaceuticals PLC agreed to sell the rights and assets for two generic drugs, and relinquish its U.S. marketing rights to a third generic drug, in order to settle FTC charges that its proposed $2 billion acquisition of Roxane would likely be anticompetitive. The merger would have combined two of five firms marketing prednisone tablets and two of four firms marketing lithium carbonate capsules. In the market for flecainide tablets, Roxane is currently one of only two firms with significant market share. Absent the merger, Hikma was expected to market flecainide tablets in the U.S. following FDA approval, which its partner, Unimark, is currently seeking. The order preserves competition by requiring the companies to divest to Pennsylvania-based Renaissance Pharma, Inc., three strengths of anti-inflammatory and immunosuppressant prednisone tablets and all strengths of lithium carbonate capsules, used to treat bipolar disorder. The order also requires Hikma to relinquish to its drug development partner, India-based Unimark Remedies Ltd., its equity interest as well as the rights to market flecainide acetate tablets in the United States, a drug used to prevent and treat abnormally fast heart rhythms.